Bibliography
- O'BYRNE KJ, DALGLEISH AG, BROWNING MJ, STEWARDWP, HARRIS AL: The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur. J. Cancer (1999) 36:151–169.
- FOX SB, LEEK RD, WEEKS MP et al.: Quantitation andprognostic value of breast cancer angiogenesis: comparison of microvessel density, chalkley count and computer image analysis. J. Pathol. (1995) 177:275–283.
- FOLKMAN J: Tumor angiogenesis: therapeutic implica-tions. N Engl. J. Med. (1971) 285:1182–1186.
- BOEHM-VISWANATHAN T: Is angiogenesis inhibition the holy grail of cancer therapy? Curr. Opin. Oncol (2000) 12:89–94.
- KERBEL RS: Tumor angiogenesis: past present and near future. Carcinogenesis (2000) 21 (3) :505–515.
- FOLBERG R, HENDRIX MJC, MANIOTIS AJ: Vasculogenic mimicry and tumor angiogenesis. Am. J. Path. (2000) 156:361–381.
- NUGENT MA, IOZZO RV: Fibroblast growth factor-2. Int. Biochem,. Cell Biol. (2000) 32 (2) :115–20.
- •An excellent review on bFGF and its pharmacology.
- LEVITZKI A: Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharm. Therap. (1999) 82 (2-3) 231–9
- TRAXLER P: Tyrosine kinase inhibitors in cancer treatment (part II). Exp. Opin. Ther. Patents (1998) 8(12):1599–1625.
- •An excellent review on TKIs.
- SHALINSKY DR: MMP inhibitors: multimodal anticancer agents in pivotal trials. Curr. Opin. Onc. End. Metab. Invest. Drugs (1999) 1(5):473–474.
- SUGITA K: Recent advances in inhibitors of matrix metalloproteinases for cancer therapy. Curr. Opin. Onc. End. Metab. Invest. Drugs (1999) 1(5):475–487.
- •This article is an excellent review of the competitive landscape of MMPIs.
- CollaGenex Reports Encouraging Findings From Metastat Clinical Study. Business Wire (April 5 2000).
- FRIEDLANDER M, BROOKS PC, SHAFFER RW etal.: Defini-tion of two angiogenic pathways by distinct a, integrins. Science (1995) 270 (5241) :1500–1502.
- LINDAHL P, BOSTROEM H, KARLSSON L, HELLSTROEM M, KALEN M, BETSHOLTZ C: Role of platelet-derived growth factors in angiogenesis and alveogenesis. Curr. Topics Pathol. (1999) 93:27–33.
- SCHLESSINGER J: New roles for Src kinases in control of cell survival and angiogenesis. Cell (2000) 100:293–296
- SWIERCZ R, SKRZYPCZAK-JANKUN E, MERRELL MM, SELMAN SH, JANKUN J: Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol. Reports (1999) 6:523–526.
- HORNIG C, WEICH HA: Soluble VEGF receptors. Angiogenesis (1999) 2:33–39.
- Genentech to proceed with Phase III trials of experi-mental anti-angiogenesis monoclonal antibody: primary objectives met in Phase II trials for colorectal and non-small cell lung cancer. M2 Presswire (December 211999).
- Schwarz Pharma/Cephalon link up. Scrips (December 17 1999).
- STADLER WM, KUZEL T, SHAPIRO C et al.: Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. 17(02541–2545.
- FUJIOKA T, FURIHATA K., KANEKO I, TAKAHASHI S, SETO H: Complestatin. J. Antibiotics (1988) 41:606.
- Cell Therapeutics, Inc. Submits NDA (new drug application) for Arsenic Trioxide. Scrip Daily News (March 31 2000).
- ROCKWELL S: Oxygen delivery: implications for the biology and therapy of solid tumors. Oncology Research (1997) 9(6–7)383–90.
- SINCOCK PM, FITTER S, PARTON RG et al.: PETA-3/CD151, a member of the transmembrane 4 superfamily, is localised to the plasma membrane and endocytic system of endothelial cells, associates with multiple integrins and modulates cell function. J. Cell ScL (1999) 112 (6):833–44.